<DOC>
	<DOCNO>NCT02310022</DOCNO>
	<brief_summary>Comparative bioavailability pharmacodynamics effect MAT9001 versus active omega-3 medication comparator .</brief_summary>
	<brief_title>A PK PD Study Two Formulations Omega-3 One Gram Capsules</brief_title>
	<detailed_description>The primary objective determine comparative bioavailability pharmacodynamics effect single multiple dos MAT9001 versus active omega-3 medication comparator .</detailed_description>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<criteria>Subjects must fulfil follow inclusion criterion eligible participation study , unless otherwise specify : 1 . Adult male female subject , 1870 year age , inclusive . 2 . Light nonsmoking , male female subject , 18 70 year age . Note : subject regularly smoke great 10 cigarette per day consider lightsmokers include . Additionally , use cigar , pipe , vapor inhaler tobacco contain product prohibit within 6 month prior drug administration . 3 . Body mass index ( BMI ) ≥ 19 ≤ 40 ( kg/m2 ) . 4 . No clinically significant finding vital sign measurement . The acceptable range seat systolic blood pressure 90150 mmHg diastolic blood pressure 5095 mmHg . 5 . No clinically significant abnormal laboratory value , opinion investigator , would compromise subject 's safety integrity study result . 6 . Either : elevate triglyceride level ( 2.26 4.52 mmol/L [ 200 400 mg/dL ] ) , · triglyceride level 2.26 3.95 mmol/L ( 200 350 mg/dL ) stable statin therapy . 7 . Total cholesterol level ≤ 7.75 mmol/L ( ≤ 300 mg/dL ) . 8 . Hemoglobin ≥ 135 g/L male ≥ 120 g/L female screen . 9 . No clinically significant finding 12lead electrocardiogram ( ECG ) 10 . Have significant disease . 11 . Willing use acceptable , effective method contraception . 12 . Be inform nature study give write consent prior study procedure . 13 . Have clinically significant finding physical examination . Subjects may exclude study evidence follow criterion screen , checkin , time study , appropriate : 1 . History presence significant cardiovascular , pulmonary , hepatic , renal , haematological , gastrointestinal ( GI ) , endocrine , immunologic , dermatologic , neurological , psychiatric disease opinion PI . 2 . Personal familial history bleed disorder ( ) , thromboembolic disease , clinical GI bleeding , history GI surgery except uncomplicated appendectomy cholecystectomy , colorectal surgery polyp , nonmalignant tumor , diverticulum . 3 . Positive urine drug/alcohol test screen checkin . 4 . Positive result human immunodeficiency virus ( HIV ) , hepatitis B surface antigen ( HBsAg ) , hepatitis C antibody ( HCV ) . 5 . History presence alcoholism drug abuse within past 2 year . 6 . Known sensitivity allergy fish , shellfish , gelatin omega3 product . 7 . Subject female pregnant lactating . 8 . Use drug know induce inhibit hepatic drug metabolism within 30 day prior drug administration 9 . Donation blood significant blood loss within 56 day prior check . 10 . Participation another clinical trial within 30 day prior drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>